Logo for Viking Therapeutics Inc

Viking Therapeutics Investor Relations Material

Latest events

Logo for Viking Therapeutics Inc

Q3 2023

Viking Therapeutics
Logo for Viking Therapeutics

Q3 2023

25 Oct, 2023
Logo for Viking Therapeutics

Q2 2023

26 Jul, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to treat metabolic, endocrine and other central nervous system disorders. The company focuses on treatments for patients with liver disease, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease and fibrosis; diabetes; thyroid diseases; and those suffering from adrenoleukodystrophy (ALD) and X-linked adrenoleukodystrophy (X-ALD). For NASH, it develops VK2809 - an orally available tissue and receptor-subtype selective agonist of thyroid hormone receptor beta (TRß) which is also in Phase IIb clinical trials for the treatment of patients with biopsy-confirmed NAFLD. Additional programs include VK0603 and VK0612 - orally available non-steroidal selective androgen receptor modulator drugs that are in Phase IIb clinical trials for the treatment of patients recovering from hip fractures; VK0612 is in Phase IIc clinical trials for type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Diego, California.